ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Approves of SKYRIZI? for Moderate to Severe Plaque Psoriasis americanpharmaceuticalreview
April 26, 2019AbbVie announced the U.S. Food and Drug Administration (FDA) approved SKYRIZI? (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or photothe
Pharma Sources Insight January 2025
